HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Building Viagra As Pan-European Consumer Health Brand With Rx-To-OTC Switch In Norway

Executive Summary

Pfizer has taken the first steps towards turning its Viagra erectile dysfunction treatment into a pan-European OTC brand by taking advantage of Norway's new "non-prescription medicines with guidance" category to secure the Rx-to-OTC switch of the product. Norway will be the second European market where Viagra is available OTC after the UK switched the drug in 2017.

You may also be interested in...



Viagra Connect To Launch In Ireland Following Rx-to-OTC Switch

Viagra will soon be available OTC in Ireland following a successful switch, but patients will have to complete a mandatory consultation with a pharmacist before the ED treatment can be supplied.

Colgate Secures Rx-To-OTC Switch Of Duraphat In Norway

Colgate's high-fluoride toothpaste Duraphat will soon be available OTC in Norway after the country switched the product into its new "non-prescription medicines with guidance" category.

Fortacin: EMA Recommends Fifth EU-Wide Rx-to-OTC Switch

Premature ejaculation treatment Fortacin is set to become only the fifth drug to achieve an Rx-to-OTC switch through European Medicines Agency's centralized procedure, expanding the burgeoning OTC men's sexual health category. 

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1131867

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel